Biotech Stock Performance Review -- Cyclacel Pharma, TG Therapeutics, Vericel, and Achaogen
NEW YORK, October 9, 2017 /PRNewswire/ --
If you want a Stock Review on CYCC, TGTX, VCEL, or AKAO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. This morning's attention is redirected to the Biotech industry, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Biotech companies are almost always unprofitable (some suggest that the distinction between "biotech" and "pharmaceutical company" lies in profitability), and many have no real revenue at all. Ahead of today's trading session, DailyStockTracker.com monitors Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC), TG Therapeutics Inc. (NASDAQ: TGTX), Vericel Corp. (NASDAQ: VCEL), and Achaogen Inc. (NASDAQ: AKAO). These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at:
http://dailystocktracker.com/register/
Cyclacel Pharmaceuticals
Berkeley Heights, New Jersey headquartered Cyclacel Pharmaceuticals Inc.'s shares declined 1.48%, finishing last Friday's session at $2.00. A total volume of 569,688 shares was traded. Over the last month, the stock has advanced 21.21%. The Company's shares are trading above their 50-day moving average by 14.75%. Additionally, shares of Cyclacel Pharma, which focuses on the development and commercialization of small molecule drugs for the treatment of cancer and other diseases, have a Relative Strength Index (RSI) of 58.61. Your complete research report on CYCC can be retrieved for free at:
http://dailystocktracker.com/registration/?symbol=CYCC
TG Therapeutics
On Friday, shares in New York headquartered TG Therapeutics Inc. ended the session 0.41% higher at $12.30. The stock recorded a trading volume of 553,442 shares. The Company's shares have gained 17.70% in the previous three months and 164.52% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 6.12% and 25.90%, respectively. Moreover, shares of TG Therapeutics, which focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the US, have an RSI of 60.03.
On October 05th, 2017, TG Therapeutics announced that the first patient has been dosed in a Phase-1 clinical trial evaluating the safety and tolerability of its proprietary fully-human anti-PD-L1 monoclonal antibody. This first-in-human, Phase-I, open-label, multicenter study is evaluating the safety and tolerability of ascending doses of the Company's anti-PD-L1 monoclonal antibody in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers. A free report on TGTX is just a click away at:
http://dailystocktracker.com/registration/?symbol=TGTX
Vericel
Cambridge, Massachusetts headquartered Vericel Corp.'s stock plummeted 7.55%, to close the day at $4.90. A total volume of 1.50 million shares was traded, which was above their three months average volume of 661,580 shares. The Company's shares have advanced 10.11% in the last one month, 44.12% over the previous three months, and 63.33% since the start of this year. The stock is trading 17.76% and 53.91% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Vericel, which researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions, have an RSI of 49.58.
On October 05th, 2017, Vericel reported that it provided a general business update at the 2017 Cell & Gene Meeting on the Mesa. The Company announced that, effective October 01st, 2017, UnitedHealthcare updated its medical policy for autologous chondrocyte implantation in the knee to include MACI® (autologous cultured chondrocytes on porcine collagen membrane). The Company also announced that it met with the US FDA on September 29th, 2017, to discuss the potential for an accelerated approval pathway for ixmyelocel-T for the treatment of patients with advanced heart failure. Sign up for your complimentary research report on VCEL at:
http://dailystocktracker.com/registration/?symbol=VCEL
Achaogen
Shares in South San Francisco, California-based Achaogen Inc. recorded a trading volume of 504,186 shares. The stock ended at $15.26, down 3.96% from the last trading session. The Company's shares have gained 17.20% on an YTD basis. The stock is trading below its 50-day moving average by 12.52%. Furthermore, shares of Achaogen, which discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the US, have an RSI of 38.08.
On September 18th, 2017, Achaogen announced the addition of Ms. Liz Bhatt as Chief Business Officer, effective that day. Ms. Bhatt will report to Blake Wise, President and COO. Most recently, she held the position of Vice President, Corporate Development at Gilead Sciences, where she was responsible for executing licenses, acquisitions, and collaborations across all of the company's therapeutic areas. Register for free on DailyStockTracker.com and download the latest research report on AKAO at:
http://dailystocktracker.com/registration/?symbol=AKAO
--
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number:(207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com
Share this article